Enter multiple symbols separated by commas



  • New Alzheimer's drugs timeline Friday, 12 Jun 2015 | 1:05 PM ET
    New Alzheimer's drugs timeline

    How Alzheimer's drug Solanezumab works to help treat the underlying cause of the disease, with CNBC's Meg Tirrell.

  • June 12- Forty percent of patients, most with a particularly aggressive form of leukemia, responded to an experimental Agios Pharmaceuticals Inc drug, including several who experienced complete remission, according to data presented on Friday. "There's nothing that tells me this isn't going to still become the standard of care," said Cowen and Co analyst Eric...

  • NEW YORK, June 11- A U.S. jury on Thursday said Pfizer Inc was not responsible for birth defects in a young girl whose mother took its antidepressant Zoloft while pregnant, the second straight win for the company out of hundreds of similar lawsuits. Plaintiff Rachel Robinson claimed in her 2011 lawsuit that Pfizer failed to warn that using Zoloft during pregnancy...

  • A small step before a huge leap to 3-D printed body Thursday, 11 Jun 2015 | 1:03 PM ET
    NSF-funded small business TeVido BioDevices uses 3-D bioprinting of a woman's own living cells to develop custom grafts for breast cancer reconstruction; the first product is targeted to improve nipple reconstruction, where current procedures often flatten and fade over time.

    TeVido BioDevices is creating a 3-D-printed female nipple, after a surge in breast cancer mastectomies created a huge health-care issue.

  • More than a third of India's 2.1 million HIV/AIDS patients depend on getting their daily antiretrovirals for free from state-run distribution centres, but many of them have been facing shortages or stock outs for months. The notice put out by the Central Board of Excise and Customs this week intends to make it cheaper to import raw materials that are used to...

  • Watershed moment for 'female Viagra' Thursday, 11 Jun 2015 | 5:20 AM ET
    Watershed moment for 'female Viagra'

    Cindy Whitehead, co-founder and CEO of Sprout Pharmaceuticals, discusses its drug "flibanserin," also known as the "female Viagra."

  • FDA panel backs first-in-class cholesterol drug Wednesday, 10 Jun 2015 | 8:44 AM ET
    Leonard Schliefer, CEO of Regeneron.

    Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.

  • MIAMI, June 9- Cathay Pacific Airways Ltd has seen a drop in bookings from Hong Kong to cities in South Korea, where cases of Middle East Respiratory Syndrome have recently increased, Chief Executive Ivan Chu said Tuesday. On Tuesday, Hong Kong issued a "red alert" advisory against non-essential travel to South Korea, where eight new cases of MERS were reported.

  • June 8- Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. Januvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in...

  • A major inflection point for US health-care costs Monday, 8 Jun 2015 | 9:19 AM ET
    Medicine doctor blood pressure

    Two divergent U.S. core inflation readings could be related to the price of medical care. CNBC explores.

  • CHICAGO, June 8- The death of more than 46 million chickens and turkeys in a bird flu outbreak is opening a rare fissure within the usually tight-knit U.S. poultry industry, pitting farmers with infected flocks against those who so far largely have sidestepped the worst outbreak in U.S. history. Hard-hit turkey producers in the Midwest say they will continue to...

  • June 7- Novo Nordisk's IDegLira combination drug for type 2 diabetes led to significant reductions in blood sugar, weight and rate of hypoglycemia compared with Sanofi's top-selling Lantus insulin product, according to data from a late-stage trial presented at a medical meeting on Sunday. In the 26- week, 557- patient phase III study presented at the ADA...

  • June 6- A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. More patients in the studies who received Lilly's basal insulin peglispro also got their blood sugar down to the...

  • Evolent Health: Reduced costs, healthier patients Friday, 5 Jun 2015 | 10:23 AM ET
    Evolent Health: Reduced costs, healthier patients

    Evolent Health CEO Frank Williams, discusses saving costs for both the patients and hospitals, with its mission to better inform health providers.

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca's cancer drugs in combination with Juno's CAR-T cell therapy, which is considered to be a breakthrough in...

  • FDA panel to discuss Lilly's lung cancer drug approval Tuesday, 2 Jun 2015 | 11:10 AM ET

    June 2- The U.S. Food and Drug Administration said a panel of experts would discuss a marketing application from Eli Lilly& Co on a new targeted lung cancer treatment. The FDA said the panel would review data that showed improved overall survival rate in lung cancer patients treated with a combination of Lilly's experimental drug, necitumumab, and chemotherapy...

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • Pfizer gaining market share in oncology: CEO Monday, 1 Jun 2015 | 1:09 PM ET
    Ian Read, CEO of Pfizer.

    Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.

  • Merck's fight against cancer Monday, 1 Jun 2015 | 1:08 PM ET
    Merck's fight against cancer

    Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.

  • Biotech isn't only health-care bet beating market Monday, 1 Jun 2015 | 10:09 AM ET
    An employee works on a stent graft component in a sterile environment at the Medtronic assembly plant in Tijuana, Mexico.

    The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.